Top

Published in:

01-02-2018 | Position Statement

A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology

Authors: Riemer H. J. A. Slart, Andor W. J. M. Glaudemans, Patrizio Lancellotti, Fabien Hyafil, Ron Blankstein, Ronald G. Schwartz, Wael A. Jaber, Raymond Russell, Alessia Gimelli, François Rouzet, Marcus Hacker, Olivier Gheysens, Sven Plein, Edward J. Miller, Sharmila Dorbala, Erwan Donal, Document Reading Group

Published in: Journal of Nuclear Cardiology | Issue 1/2018

Excerpt

Document Reading Group
Roberto Sciagra^a	Danilo Neglia^k
Jan Bucerius^b,c,d	Rob S. Beanlands^l
Hein J. Verberne^e	Marcelo Di Carli^m,n
Oliver Lindner^f	Panithaya Chareonthaitawee^o
Christopher Übleis^g	Vasken Dilsizian^p
Denis Agostini^h	Prem Soman^q
Alberto Signoreⁱ	Gilbert Habib^r
Thor Edvardsen^j

^aNuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

^bDepartment of Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands

^cCardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center, Maastricht, The Netherlands

^dDepartment of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany

^eDepartment of Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands

^fInstitute of Radiology Nuclear Medicine and Molecular Imaging, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

^gDepartment of Clinical Radiology, Ludwig-Maximilians Universität München, Munich, Germany

^hDepartment of Nuclear Medicine, CHU Cote de Nacre, Caen, France

ⁱNuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, ‘Sapienza’ University of Roma, Rome, Italy

^jDepartment of Cardiology, Oslo University Hospital, Rikshospitalet and University of Oslo, Oslo, Norway

^kFondazione Toscana/CNR Gabriele Monasterio, Pisa, Italy

^lDivision of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, Canada

^mDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA

ⁿ Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA

^oDepartment of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA

^pDepartment of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, Baltimore, MD, USA

^qDivision of Cardiology Heart and Vascular Institute, University of Pittsburgh Medical Center, A-429 Scaife Hall 200 Lothrop Street, Pittsburgh, PA, 15213, USA

^rDepartment of Cardiology, Aix-Marseille Université, Marseille 13284, France La Timone Hospital, 13005, Marseille, France

EACVI Reviewers:
This document was reviewed by members of the EACVI Scientific Documents Committee for 2014–2016 and 2016–2018:
Victoria Delgado	Bernhard Gerber
Nuno Cardim	Kristina Haugaa
Bernard Cosyns	Massimo Lombardi
Frank Flachskampf	Pier Giorgio Masci

…

Available only for authorised users

Ungprasert P, Carmona EM, Utz JP, Ryu JH, Crowson CS, Matteson EL. Epidemiology of sarcoidosis 1946–2013: A population-based study. Mayo Clin Proc 2016;91:183-8.PubMedCrossRef

Baughman RP, Teirstein AS, Judson MA, Rossman MD, Yeager H Jr, Bresnitz EA. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med 2001;164:1885-9.PubMedCrossRef

Lynch JP III, Hwang J, Bradfield J, Fishbein M, Shivkumar K, Tung R. Cardiac involvement in sarcoidosis: Evolving concepts in diagnosis and treatment. Semin Respir Crit Care Med 2014;35:372-90.PubMedPubMedCentralCrossRef

Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med 1995;119:167-72.PubMed

Silverman KJ, Hutchins GM, Bulkley BH. Cardiac sarcoid: A clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 1978;58:1204-11.PubMedCrossRef

Nelson JE, Kirschner PA, Teirstein AS. Sarcoidosis presenting as heart disease. Sarcoidosis Vasc Diffuse Lung Dis 1996;13:178-82.PubMed

Kim JS, Judson MA, Donnino R, Gold M, Cooper LT Jr, Prystowsky EN. Cardiac sarcoidosis. Am Heart J 2009;157:9-21.PubMedCrossRef

Yazaki Y, Isobe M, Hiroe M, Morimoto S, Hiramitsu S, Nakano T. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001;88:1006-10.PubMedCrossRef

Japanese Ministry Health Welfare. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord (Jpn) 2007;27:89-102.

10.

Birnie DH, Sauer WH, Bogun F, Cooper JM, Culver DA, Duvernoy CS. HRS Expert Consensus Statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305-23.PubMedCrossRef

11.

Cardim N, Galderisi M, Edvardsen T, Plein S, Popescu BA, D’andrea A. Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy: An Expert Consensus of the European Association of Cardiovascular Imaging Endorsed by the Saudi Heart Association. Eur Heart J Cardiovasc Imaging 2015;16:280.PubMedCrossRef

12.

Cosyns B, Plein S, Nihoyanopoulos P, Smiseth O, Achenbach S, Andrade MJ. European Association of Cardiovascular Imaging (EACVI) position paper: Multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging 2014;16:12-31.PubMedCrossRef

13.

Flachskampf FA, Wouters PF, Edvardsen T, Evangelista A, Habib G, Hoffman P. Recommendations for transoesophageal echocardiography: EACVI update 2014. Eur Heart J Cardiovasc Imaging 2014;15:353-65.PubMedCrossRef

14.

Lancellotti P, Tribouilloy C, Hagendorff A, Popescu BA, Edvardsen T, Pierard LA. Recommendations for the echocardiographic assessment of native valvular regurgitation: An executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2013;14:611-44.PubMedCrossRef

15.

Lang RM, Badano LP, Tsang W, Adams DH, Agricola E, Buck T. EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography. Eur Heart J Cardiovasc Imaging 2012;13:1-46.PubMedCrossRef

16.

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16:233-70.PubMedCrossRef

17.

Mor-Avi V, Lang RM, Badano LP, Belohlavek M, Cardim NM, Derumeaux G. Current and evolving echocardiographic techniques for the quantitative evaluation of cardiac mechanics: ASE/EAE Consensus Statement on methodology and indications endorsed by the Japanese Society of Echocardiography. J Am Soc Echocardiogr 2011;24:277-313.PubMedCrossRef

18.

Popescu BA, Stefanidis A, Nihoyannopoulos P, Fox KF, Ray S, Cardim N. Updated standards and processes for accreditation of echocardiographic laboratories from The European Association of Cardiovascular Imaging: An executive summary. Eur Heart J Cardiovasc Imaging 2014;15:1188-93.PubMedCrossRef

19.

Aggarwal NR, Snipelisky D, Young PM, Gersh BJ, Cooper LT, Chareonthaitawee P. Advances in imaging for diagnosis and management of cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging 2015;16:949-58.PubMedCrossRef

20.

Focardi M, Picchi A, Nikiforakis N, Bargagli E, Fossi A, Maggiorelli C. Assessment of cardiac involvement in sarcoidosis by echocardiography. Rheumatol Int 2009;29:1051-5.PubMedCrossRef

21.

Lewin RF, Mor R, Spitzer S, Arditti A, Hellman C, Agmon J. Echocardiographic evaluation of patients with systemic sarcoidosis. Am Heart J 1985;110:116-22.PubMedCrossRef

22.

Burstow DJ, Tajik AJ, Bailey KR, DeRemee RA, Taliercio CP. Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol 1989;63:478-82.PubMedCrossRef

23.

Chiu CZ, Nakatani S, Zhang G, Tachibana T, Ohmori F, Yamagishi M. Prevention of left ventricular remodeling by long-term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005;95:143-6.PubMedCrossRef

24.

Jain A, Starek PJ, Delany DL. Ventricular tachycardia and ventricular aneurysm due to unrecognized sarcoidosis. Clin Cardiol 1990;13:738-40.PubMedCrossRef

25.

Patel MB, Mor-Avi V, Murtagh G, Bonham CA, Laffin LJ, Hogarth DK. Right heart involvement in patients with sarcoidosis. Echocardiography 2016;33:734-41.PubMedCrossRef

26.

Vasaiwala SC, Finn C, Delpriore J, Leya F, Gagermeier J, Akar JG. Prospective study of cardiac sarcoid mimicking arrhythmogenic right ventricular dysplasia. J Cardiovasc Electrophysiol 2009;20:473-6.PubMedCrossRef

27.

Degirmenci H, Demirelli S, Arisoy A, Ermis E, Araz O, Bakirci EM. Myocardial deformation and total atrial conduction time in the prediction of cardiac involvement in patients with pulmonary sarcoidosis. Clin Respir J 2017;11:68-77.PubMedCrossRef

28.

Joyce E, Ninaber MK, Katsanos S, Debonnaire P, Kamperidis V, Bax JJ. Subclinical left ventricular dysfunction by echocardiographic speckle-tracking strain analysis relates to outcome in sarcoidosis. Eur J Heart Fail 2015;17:51-62.PubMedCrossRef

29.

Kul S, Ozcelik HK, Uyarel H, Karakus G, Guvenc TS, Yalcınsoy M. Diagnostic value of strain echocardiography, galectin-3, and tenascin-C levels for the identification of patients with pulmonary and cardiac sarcoidosis. Lung 2014;192:533-42.PubMedCrossRef

30.

Orii M, Hirata K, Tanimoto T, Shiono Y, Shimamura K, Yamano T. Myocardial damage detected by two-dimensional speckle-tracking echocardiography in patients with extracardiac sarcoidosis: Comparison with magnetic resonance imaging. J Am Soc Echocardiogr 2015;28:683-91.PubMedCrossRef

31.

Saeed IM, Coggins T, Main ML, Bateman TM. Cardiac sarcoidosis with visually normal wall motion: Role of cardiac MRI, FDG PET, and strain echocardiography. Eur Heart J Cardiovasc Imaging 2015;16:1275.PubMedCrossRef

32.

Tigen K, Sunbul M, Karaahmet T, Tasar O, Dundar C, Yalcinsoy M. Early detection of bi-ventricular and atrial mechanical dysfunction using two-dimensional speckle tracking echocardiography in patients with sarcoidosis. Lung 2015;193:669-75.PubMedCrossRef

33.

Hyodo E, Hozumi T, Takemoto Y, Watanabe H, Muro T, Yamagishi H. Early detection of cardiac involvement in patients with sarcoidosis by a non-invasive method with ultrasonic tissue characterisation. Heart 2004;90:1275-80.PubMedPubMedCentralCrossRef

34.

Yasutake H, Seino Y, Kashiwagi M, Honma H, Matsuzaki T, Takano T. Detection of cardiac sarcoidosis using cardiac markers and myocardial integrated backscatter. Int J Cardiol 2005;102:259-68.PubMedCrossRef

35.

Hourigan LA, Burstow DJ, Pohlner P, Clarke BE, Donnelly JE. Transesophageal echocardiographic abnormalities in a case of cardiac sarcoidosis. J Am Soc Echocardiogr 2001;14:399-402.PubMedCrossRef

36.

Nureki S, Miyazaki E, Nishio S, Ehara C, Yamasue M, Ando M. Interventricular septal thickening as an early manifestation of cardiac sarcoidosis. Int Heart J 2014;55:181-3.PubMedCrossRef

37.

Yazaki Y, Isobe M, Hayasaka M, Tanaka M, Fujii T, Sekiguchi M. Cardiac sarcoidosis mimicking hypertrophic cardiomyopathy: Clinical utility of radionuclide imaging for differential diagnosis. Jpn Circ J 1998;62:465-8.PubMedCrossRef

38.

Skold CM, Larsen FF, Rasmussen E, Pehrsson SK, Eklund AG. Determination of cardiac involvement in sarcoidosis by magnetic resonance imaging and Doppler echocardiography. J Intern Med 2002;252:465-71.PubMedCrossRef

39.

Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: Applications of imaging in diagnosis and directing treatment. Heart 2011;97:2078-87.PubMedCrossRef

40.

Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: With emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009;20:578-83.PubMedCrossRef

41.

Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M. Cardiac involvement in patients with sarcoidosis: Diagnostic and prognostic value of outpatient testing. Chest 2008;133:1426-35.PubMedCrossRef

42.

Nishiyama Y, Yamamoto Y, Fukunaga K, Takinami H, Iwado Y, Satoh K. Comparative evaluation of ¹⁸F-FDG PET and ⁶⁷Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006;47:1571-6.PubMed

43.

Treglia G, Annunziata S, Sobic-Saranovic D, Bertagna F, Caldarella C, Giovanella L. The role of ¹⁸F-FDG-PET and PET/CT in patients with sarcoidosis: An updated evidence-based review. Acad Radiol 2014;21:675-84.PubMedCrossRef

44.

Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol 2014;21:925-39.PubMedCrossRef

45.

Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-36.PubMedCrossRef

46.

Koiwa H, Tsujino I, Ohira H, Yoshinaga K, Otsuka N, Nishimura M. Images in cardiovascular medicine: Imaging of cardiac sarcoid lesions using fasting cardiac ¹⁸F-fluorodeoxyglucose positron emission tomography: An autopsy case. Circulation 2010;122:535-6.PubMedCrossRef

47.

Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972-80.PubMed

48.

Newsholme P, Newsholme EA. Rates of utilization of glucose, glutamine and oleate and formation of end-products by mouse peritoneal macrophages in culture. Biochem J 1989;261:211-8.PubMedPubMedCentralCrossRef

49.

Dorbala S, Di Carli MF, Delbeke D, Abbara S, DePuey EG, Dilsizian V. SNMMI/ASNC/SCCT guideline for cardiac SPECT/CT and PET/CT 1.0. J Nucl Med 2013;54:1485-507.PubMedCrossRef

50.

Jamar F, Buscombe J, Chiti A, Christian PE, Delbeke D, Donohoe KJ. EANM/SNMMI guideline for ¹⁸F-FDG use in inflammation and infection. J Nucl Med 2013;54:647-58.PubMedCrossRef

51.

Morooka M, Moroi M, Uno K, Ito K, Wu J, Nakagawa T. Long fasting is effective in inhibiting physiological myocardial ¹⁸F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res 2014;4:1.PubMedPubMedCentralCrossRef

52.

Scholtens AM, Verberne HJ, Budde RP, Lam MG. Additional heparin preadministration improves cardiac glucose metabolism suppression over low-carbohydrate diet alone in ⁽¹⁾⁽⁸⁾F-FDG PET imaging. J Nucl Med 2015;57:568-73.PubMedCrossRef

53.

Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K. Identification of cardiac sarcoidosis with ⁽¹³⁾N-NH₍₃₎/⁽¹⁸⁾F-FDG PET. J Nucl Med 2003;44:1030-6.PubMed

54.

Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M. Focal uptake on ¹⁸F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-43.PubMedCrossRef

55.

Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N. Usefulness of fasting ¹⁸F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98.PubMed

56.

McArdle BA, Birnie DH, Klein R, de Kemp RA, Leung E, Renaud J. Is there an association between clinical presentation and the location and extent of myocardial involvement of cardiac sarcoidosis as assessed by ⁽¹⁾⁽⁸⁾F-fluorodeoxyglucose positron emission tomography? Circ Cardiovasc Imaging 2013;6:617-26.CrossRef

57.

Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting ¹⁸F-FDG PET–CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801-10.PubMedCrossRef

58.

Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010;3:1219-28.PubMedCrossRef

59.

Osborne MT, Hulten EA, Singh A, Waller AH, Bittencourt MS, Stewart GC. Reduction in ⁽¹⁾⁽⁸⁾F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2013;21:166-74.PubMedCrossRef

60.

Waller AH, Blankstein R. Quantifying myocardial inflammation using ¹⁸F-fluorodeoxyglucose positron emission tomography in cardiac sarcoidosis. J Nucl Cardiol 2014;21:940-3.PubMedCrossRef

61.

Chapelon-Abric C, de Zuttere D, Duhaut P, Veyssier P, Wechsler B, Huong DL. Cardiac sarcoidosis: A retrospective study of 41 cases. Medicine (Baltim) 2004;83:315-34.CrossRef

62.

Le GD, Menad F, Faraggi M, Weinmann P, Battesti JP, Valeyre D. Myocardial sarcoidosis. Clinical value of technetium-99m sestamibi tomoscintigraphy. Chest 1994;106:1675-82.CrossRef

63.

Dilsizian V. Highlights from the updated joint ASNC/SNMMI PET myocardial perfusion and metabolism clinical imaging guidelines. J Nucl Med 2016;57:1327-8.PubMedCrossRef

64.

Holly TA, Abbott BG, Al-Mallah M, Calnon DA, Cohen MC, DiFilippo FP. Single photon-emission computed tomography. J Nucl Cardiol 2010;17:941-73.PubMedCrossRef

65.

Sciagra R, Passeri A, Bucerius J, Verberne HJ, Slart RH, Lindner O. Clinical use of quantitative cardiac perfusion PET: Rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM). Eur J Nucl Med Mol Imaging 2016;43:1530-45.PubMedCrossRef

66.

Verberne HJ, Acampa W, Anagnostopoulos C, Ballinger J, Bengel F, De BP. EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 Revision. Eur J Nucl Med Mol Imaging 2015;42:1929-40.PubMedPubMedCentralCrossRef

67.

Kapur A, Latus KA, Davies G, Dhawan RT, Eastick S, Jarritt PH. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: The ROBUST study. Eur J Nucl Med Mol Imaging 2002;29:1608-16.PubMedCrossRef

68.

Berman JS, Govender P, Ruberg FL, Mazzini M, Miller EJ. Scadding revisited: A proposed staging system for sardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2014;31:2-5.PubMed

69.

Ohira H, Tsujino I, Ishimaru S, Oyama N, Takei T, Tsukamoto E. Myocardial imaging with ¹⁸F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933-41.PubMedCrossRef

70.

Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G. The use of ¹⁸F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241-8.PubMedCrossRef

71.

Okada DR, Bravo PE, Vita T, Agarwal V, Osborne MT, Taqueti VR. Isolated cardiac sarcoidosis: A focused review of an under-recognized entity. J Nucl Cardiol 2016 (Epub ahead of print).

72.

Okumura W, Iwasaki T, Ueda T, Seki R, Miyajima A, Hatori T. Usefulness of ¹⁸F-FDG PET for diagnosis of cardiac sarcoidosis. Kaku Igaku 1999;36:341-8.PubMed

73.

Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson 2013;15:91.PubMedPubMedCentralCrossRef

74.

Orii M, Hirata K, Tanimoto T, Ota S, Shiono Y, Yamano T. Comparison of cardiac MRI and ⁽¹⁸⁾F-FDG positron emission tomography manifestations and regional response to corticosteroid therapy in newly diagnosed cardiac sarcoidosis with complete heart block. Heart Rhythm 2015;12:2477-85.PubMedCrossRef

75.

Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, Society for Cardiovascular Magnetic Resonance: Board of Trustees Task Force on Standardized Protocols. J Cardiovasc Magn Reson 2008;10:35.PubMedPubMedCentralCrossRef

76.

Greulich S, Deluigi CC, Gloekler S, Wahl A, Zurn C, Kramer U. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013;6:501-11.PubMedCrossRef

77.

Nagai T, Kohsaka S, Okuda S, Anzai T, Asano K, Fukuda K. Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest 2014;146:1064-72.PubMedCrossRef

78.

Patel AR, Klein MR, Chandra S, Spencer KT, Decara JM, Lang RM. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: An observational study. Eur J Heart Fail 2011;13:1231-7.PubMedCrossRef

79.

Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Cheriex EC, Gorgels AP. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest 2005;128:1629-37.PubMedCrossRef

80.

Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005;45:1683-90.PubMedCrossRef

81.

Watanabe E, Kimura F, Nakajima T, Hiroe M, Kasai Y, Nagata M. Late gadolinium enhancement in cardiac sarcoidosis: Characteristic magnetic resonance findings and relationship with left ventricular function. J Thorac Imaging 2013;28:60-6.PubMedCrossRef

82.

Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.PubMedPubMedCentralCrossRef

83.

Murtagh G, Laffin LJ, Beshai JF, Maffessanti F, Bonham CA, Patel AV. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: Risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging 2016;9:e003738.PubMedPubMedCentralCrossRef

84.

Hulten E, Agarwal V, Cahill M, Cole G, Vita T, Parrish S. Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: A systematic review and meta-analysis. Circ Cardiovasc Imaging 2016;9:e005001.PubMedPubMedCentralCrossRef

85.

Shimada T, Shimada K, Sakane T, Ochiai K, Tsukihashi H, Fukui M. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001;110:520-7.PubMedCrossRef

86.

Yang Y, Safka K, Graham JJ, Roifman I, Zia MI, Wright GA. Correlation of late gadolinium enhancement MRI and quantitative T2 measurement in cardiac sarcoidosis. J Magn Reson Imaging 2014;39:609-16.PubMedCrossRef

87.

Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: A slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 1979;76:4275-9.PubMedPubMedCentralCrossRef

88.

Vignaux O, Dhote R, Duboc D, Blanche P, Dusser D, Weber S. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: A 1-year follow-up study. Chest 2002;122:1895-901.PubMedCrossRef

89.

Ardehali H, Howard DL, Hariri A, Qasim A, Hare JM, Baughman KL. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 2005;150:459-63.PubMedCrossRef

90.

Ratner SJ, Fenoglio JJ Jr, Ursell PC. Utility of endomyocardial biopsy in the diagnosis of cardiac sarcoidosis. Chest 1986;90:528-33.PubMedCrossRef

91.

Kandolin R, Lehtonen J, Graner M, Schildt J, Salmenkivi K, Kivisto SM. Diagnosing isolated cardiac sarcoidosis. J Intern Med 2011;270:461-8.PubMedCrossRef

92.

Nery PB, Keren A, Healey J, Leug E, Beanlands RS, Birnie DH. Isolated cardiac sarcoidosis: establishing the diagnosis with electroanatomic mapping-guided endomyocardial biopsy. Can J Cardiol 2013;29:1015.e1-3.CrossRef

93.

Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: A Delphi study. Chest 2012;141:154-62.PubMedCrossRef

94.

Cain MA, Metzl MD, Patel AR, Addetia K, Spencer KT, Sweiss NJ. Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias. Am J Cardiol 2014;113:1556-60.PubMedCrossRef

95.

Nadel J, Lancefield T, Voskoboinik A, Taylor AJ. Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur Heart J Cardiovasc Imaging 2015;16:634-41.PubMed

96.

Ise T, Hasegawa T, Morita Y, Yamada N, Funada A, Takahama H. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 2014;100:1165-72.PubMedCrossRef

97.

Betensky BP, Tschabrunn CM, Zado ES, Goldberg LR, Marchlinski FE, Garcia FC. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012;9:884-91.PubMedCrossRef

98.

Schuller JL, Zipse M, Crawford T, Bogun F, Beshai J, Patel AR. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol 2012;23:925-9.PubMedCrossRef

99.

Blankstein R, Waller AH. Evaluation of known or suspected cardiac sarcoidosis. Circ Cardiovasc Imaging 2016;9:e000867.PubMedCrossRef

100.

Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R. Cardiac sarcoidosis—State of the art review. Cardiovasc Diagn Ther 2016;6:50-63.PubMedPubMedCentral

101.

Schneider S, Batrice A, Rischpler C, Eiber M, Ibrahim T, Nekolla SG. Utility of multimodal cardiac imaging with PET/MRI in cardiac sarcoidosis: Implications for diagnosis, monitoring and treatment. Eur Heart J 2014;35:312.PubMedCrossRef

102.

Wada K, Niitsuma T, Yamaki T, Masuda A, Ito H, Kubo H. Simultaneous cardiac imaging to detect inflammation and scar tissue with F-fluorodeoxyglucose PET/MRI in cardiac sarcoidosis. J Nucl Cardiol 2015. doi:10.1007/s12350-015-0348-4.PubMed

103.

Harisankar CN, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol 2011;18:926-36.PubMedCrossRef

Title: A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology
Authors: Riemer H. J. A. Slart
Andor W. J. M. Glaudemans
Patrizio Lancellotti
Fabien Hyafil
Ron Blankstein
Ronald G. Schwartz
Wael A. Jaber
Raymond Russell
Alessia Gimelli
François Rouzet
Marcus Hacker
Olivier Gheysens
Sven Plein
Edward J. Miller
Sharmila Dorbala
Erwan Donal
Document Reading Group
Publication date: 01-02-2018
Publisher: Springer US
Published in: Journal of Nuclear Cardiology / Issue 1/2018
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-017-1043-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

Myocardial metabolic improvement prior to electrocardiographic or volumetric changes of the right ventricle in pulmonary arterial hypertension

Deciding wisely: A case for an effective use of myocardial perfusion imaging

The severity of ventricular arrhythmia correlates with the extent of myocardial sympathetic denervation, but not with myocardial fibrosis extent in chronic Chagas cardiomyopathy

Regadenoson use for stress myocardial perfusion imaging in advance chronic kidney disease and dialysis: Safe, effective, and efficient

Erratum to: Standardization of 99mTechnetium pyrophosphate imaging methodology to diagnose TTR cardiac amyloidosis

Influence of ROI definition on the heart-to-mediastinum ratio in planar 123I-MIBG imaging

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page